Danish Medicines Council rejects Johnson & Johnson's psoriasis medicine: "Worse than existing standard treatment"

Tremfya will not be becoming the standard treatment for psoriatic arthritis, a type of arthritis which can accompany the inflammatory skin disease.


The Danish Medicines Council has refused to recommend Johnson & Johnson's drug Tremfya as the standard treatment for psioratic arthritis in Denmark - no matter how it is priced.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs